Related Experiment Video

Updated: Apr 6, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

532

Origins, genetic landscape, and emerging therapies of small cell lung cancer

Ekaterina A Semenova1, Remco Nagel1, Anton Berns1

  • 1Division of Molecular Genetics, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.

Genes & Development
|July 30, 2015
PubMed

Insights

Small cell lung cancer (SCLC) is an aggressive subtype with poor survival rates. This review details SCLC genetics, cell origins, and targeted therapies to improve treatment options.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer, causing significant mortality.
  • Current SCLC treatments have seen limited advancement, with a 5-year survival rate below 7% for decades.
  • Genomic studies have revealed key mutations driving SCLC, confirmed in preclinical models.

Purpose of the Study:

  • To provide a comprehensive overview of the current understanding of SCLC.
  • To explore the genetic landscape and cellular origins of SCLC.
  • To discuss emerging targeted therapeutic strategies for SCLC.

Main Methods:

  • Review of existing literature on SCLC genetics and molecular biology.
  • Analysis of genomic data to identify driver mutations.
  • Examination of preclinical models for SCLC validation.
  • Synthesis of information on cellular mechanisms and therapeutic targets.

Main Results:

  • Identification of critical genetic alterations in SCLC.
  • Characterization of the cell of origin for SCLC.
  • Overview of the molecular pathways involved in SCLC progression and resistance.
  • Summary of potential targeted therapies based on genomic findings.

Conclusions:

  • A deeper understanding of SCLC's cellular and molecular underpinnings is crucial for developing effective treatments.
  • Targeted therapeutic approaches show promise for improving outcomes in SCLC.
  • Further research into SCLC initiation, progression, metastasis, and resistance mechanisms is warranted.
Keywords:
GEMMSCLCcell of origindriverneuroendocrinetargeted therapy

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN11:42

Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN

Published on: April 3, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.5K